

Pfizer Inc.  
7000 Portage Road  
Kalamazoo, MI 49001

---



Dee L. Clement  
Senior Advisor – RSO  
tel 269-833-9431  
fax 269-833-9400  
dee.l.clement@pfizer.com

February 13, 2007

Mr. George M. McCann  
Decommissioning Branch  
Nuclear Regulatory Commission, Region III  
2443 Warrenville Road STE 210  
Lisle, IL 60532-4352

Subject: Notification of Intent to permanently cease licensed activities (disposal) at the Incinerator and Decommission the Incinerator and Building 172 housing it, located at the 7000 Portage Road facility under License No. 21-00182-03, Pharmacia and Upjohn LLC.

Dear Mr. McCann:

This letter is to notify you that in accordance with 10 CFR 30.36(d), Pharmacia & Upjohn Company LLC (a subsidiary of Pfizer Inc) has decided to cease disposal activities of radioactive materials through its incinerator. We intend to decommission the incinerator and Building 172 (B172) that houses the incinerator system in 2007, future reference to B172 in this notice means the building plus its incinerator systems. Disposal of radioactive materials through the incinerator has been replaced by off-site disposal through a vendor (Duratek.)

Building 172 is located at the 7000 Portage Road facility in Kalamazoo, Michigan under Type A Broad Scope License Number 21-00182-03. B172 is a building approved by our broad scope license as a location of use but not specifically named on Pfizer's license. In accordance with NRC rules and regulations, radioactive decommissioning of Building 172 will be performed in a timely manner to permit its unrestricted use. Concurrently B172 will be decontaminated in accordance with its RCRA closure plan as a permitted hazardous waste facility.

Pfizer has retained SEC (Safety & Ecology Corp.) to perform the radioactive and hazardous waste decontaminations of the facility. SEC has initiated an historical site assessment and scoping surveys of this facility in order to prepare a Decontamination and Decommissioning (D&D) Plan following MARRISM guidelines. Scoping surveys show the incinerator systems and Building 172 contain minimal residual radioactivity therefore in-dept surveys should show the site to be suitable for release in accordance with NRC requirements. Pfizer has concluded that a formal approved D&D Plan is not required based on the information gathered during the historical site assessment and scoping surveys, however, we believe that a D&D Plan is still a prudent model to follow in order to decommission B172 in a safe and compliant manner. As a courtesy, we will send you a copy of the D&D Plan and ask that you provide us any comments in regards to its adequacy to meet the NRC's expectations to decontaminate and decommission this facility.

RECEIVED FEB 21 2007

We expect to complete these D&D activities in the next 6 months and soon after we will submit an amendment request including the D& D final report, to remove the incinerator and B172 from our license. Following NRC approval the incinerator systems will be removed (demolished) and Building 172 will remain for non-radioactive activities.

I appreciate your assistance with completing yet another decommissioning. Please contact me if you have any questions concerning this notification.

Sincerely, 

Dee L. Clement Radiation Safety Officer - Kalamazoo Site

cc: Kevin Null (NRC)

Dee L.           nt Unit 4K418  
Pfizer Inc.  
7000 Portage Road  
Kalamazoo, MI 49001



7002 2410 0002 7673 1398

PRESORTED  
FIRST CLASS



44  
U.S. POSTAGE

0464

H METER 708568

Mr. George M. McCann  
Decommissioning Branch  
Nuclear Regulatory Commission, Region III  
2443 Warrenville Road STE 21  
Lisle, IL 60532-4352